Business Wire India

• The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).²
• The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.^3,4
• Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in more than 40 countries.

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond IPF.¹ The opinion is based on the positive results of the INBUILD^® phase III trial, the first study to evaluate adults with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behaviour.² This follows the FDA’s and Health Canada’s approval of nintedanib as the first treatment for the same patient population.^3,4

Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.⁵ People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality similar to those with IPF, the most frequent form of idiopathic interstitial pneumonias.⁶ The course of the disease and the symptoms are similar in progressive forms of chronic fibrosing ILDs regardless of the underlying ILD diagnosis, and as many as 18% to 32% of patients with non-IPF ILDs are estimated to be at risk for developing a progressive fibrosing disease behavior.^7,8

“Pulmonary fibrosis is a major challenge for people suffering with ILDs and can lead to irreversible harm to the lungs, resulting in worsening respiratory symptoms and reduced quality of life,” commented Peter Fang, Senior Vice President and Head of Therapeutic Area Inflammation at Boehringer Ingelheim. “We are very pleased with the Committee’s opinion, which can bring a new therapy to people where there are no currently approved treatment options available.”

The positive opinion is based on the results of INBUILD^®, a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype.² The primary endpoint was the annual rate of decline in forced vital capacity (FVC) in mL assessed over a 52-week period. Patients on placebo lost 188mL lung volume over a year, while patients on nintedanib lost 81mL. This was measured as adjusted annual rate of decline over 52 weeks and meant that nintedanib slowed the lung function decline by 57% versus placebo.² The treatment effect of nintedanib in slowing FVC decline compared with placebo seen in INBUILD^® was consistent for all patients, regardless of the fibrotic pattern on high-resolution computed tomography (HRCT) and it was also consistent with the results in nintedanib trials studying patients with IPF and SSc-ILD.^2,9,10,11

In the trial, nintedanib was associated with numerical reductions in the risk of acute exacerbation or death versus placebo.² Treatment benefit may also be accompanied by reduced worsening of patient-reported outcomes such as dyspnea and cough.¹² In addition, the safety profile observed in INBUILD^® was consistent to what has been seen in IPF and SSc-ILD patients treated with nintedanib previously.²

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/chmpopinionnintedanibildpf

View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005287/en/